Hot flashes and night sweats — what's actually happening at the hypothalamic level

For a long time, the explanation offered was blunt: estrogen goes down, hot flashes happen. Which is true as far as it goes, but doesn't tell you anything about the specific mechanism — why estrogen decline specifically triggers false heat signals, or why some women have them dozens of times a day and others rarely, or why they eventually diminish even when estrogen stays low. The actual biology has only been elucidated clearly in the last decade, and it has changed what treatments are now possible.

Here is what's happening at the hypothalamic level.

The hypothalamus is your body's thermoregulatory headquarters. It runs a continuous set-point system: body temperature goes above threshold, and the hypothalamus triggers heat-dissipation responses — vasodilation, sweating, heat flushing to the skin. Normal. Appropriate. The problem in menopause is that the trigger gets dysregulated, so the heat-dissipation response fires when there is no actual heat excess to dissipate. The false alarm comes from a specific cluster of neurons in the hypothalamus called the KNDy neurons — an acronym for the three neuropeptides they co-express: kisspeptin, neurokinin B, and dynorphin.

KNDy neurons are involved in regulating the pulsatile release of GnRH, the gonadotropin-releasing hormone that initiates the hormonal cascade governing reproductive function. But they also have a critical role in thermoregulation, and this is where the problem lives. In the premenopausal state, estrogen keeps KNDy neuronal activity in check. Estrogen receptors on these neurons receive estrogen's signal and it damps their activity — keeps the firing rate calibrated. When estrogen declines, that dampening signal disappears. The KNDy neurons, no longer receiving the inhibitory estrogen signal, become hyperactive. Specifically, neurokinin B — one of the three neuropeptides these neurons release — activates neurokinin 3 (NK3) receptors in the hypothalamic thermoregulatory center. That activation is interpreted as a heat alarm. The body responds with a genuine heat-dissipation response. Your vasculature dilates. You sweat. Your skin flushes. The body is doing exactly what it was designed to do — it's just responding to a false signal generated by overactive neurons that estrogen used to hold quiet.

This mechanism explains several things that weren't intuitive under the old "estrogen goes down, hot flashes happen" framing. It explains why hot flashes tend to be worst not at peak menopause but during the transition — the estrogen decline itself, and its variability, is more destabilizing than a sustained low-estrogen state, because the KNDy neurons are reacting to a shifting baseline rather than a stable one. It explains why some women eventually experience fewer flashes even without estrogen replacement — the KNDy neurons downregulate over time in the low-estrogen environment, adapting to the new set point. And it explains why a non-hormonal treatment is now possible that directly targets this pathway.

In 2023, the FDA approved fezolinetant, sold under the brand name Veozah, as the first non-hormonal treatment specifically designed to target the KNDy neuron mechanism. Fezolinetant is a neurokinin 3 receptor antagonist — it blocks the NK3 receptor that neurokinin B activates in the hypothalamic thermoregulatory center, quieting the false alarm signal without introducing exogenous hormones. Clinical trials demonstrated meaningful reductions in the frequency and severity of moderate-to-severe vasomotor symptoms. This is not a lifestyle intervention or an off-label repurposing; it is a mechanistically specific treatment developed directly from the research that identified KNDy neurons as the mediator. For women who cannot or prefer not to use hormonal therapy, its approval represents a significant shift in what the non-hormonal treatment landscape can offer.

The long-established treatment — and still, for most women, the most effective one — is menopausal hormone therapy. MHT, also called HRT, addresses the root of the KNDy hyperactivation by restoring estrogen levels, which re-establishes the inhibitory signal the neurons are missing. Estrogen alone, for women without a uterus; estrogen plus progesterone or a progestogen, for women with a uterus, because progesterone protects the uterine lining from the proliferative effects of estrogen unopposed. The 2002 Women's Health Initiative findings created a generation of undertreatment — the WHI studied older women with a different cardiovascular risk profile on a specific oral combined regimen and generated headlines that were applied broadly and inaccurately to all HRT in all women. The current evidence, reanalyzed by menopause specialists, is more nuanced: for healthy women under sixty or within ten years of menopause onset, MHT has a favorable benefit-risk profile and is endorsed by the Menopause Society as the most effective treatment for vasomotor symptoms. The route of administration matters — transdermal estrogen carries different risk considerations than oral formulations, particularly for thromboembolism. The specific progestogen matters. These are not decisions to make from a webpage; they are conversations with a menopause-trained clinician who knows your history.

It's worth distinguishing between FDA-approved MHT formulations and compounded bioidentical preparations. Conventional MHT is available in forms that have undergone clinical trials and FDA review for safety and efficacy. Many compounded bioidentical hormone preparations — custom-mixed progesterone creams, estriol preparations, combinations not available commercially — are not FDA-approved, meaning they have not undergone the same standardized testing for purity, potency, or consistent dosing. Some women prefer compounded formulations for reasons including specific delivery preferences or hormone combinations; that preference is worth discussing with a prescribing provider with transparency about what has and hasn't been formally tested.

Peptides occupy a more limited and indirect role in the vasomotor symptom picture. No peptide has been specifically researched as a treatment for hot flashes in the way fezolinetant has been developed for that indication. What exists is adjacent and mechanistic. For the sleep disruption component of vasomotor symptoms — the night sweats that fragment architecture, reduce slow-wave sleep, and leave the nervous system in a state of sustained fatigue — sleep-supportive peptides like delta sleep-inducing peptide (DSIP) have been researched for slow-wave sleep promotion, though the clinical evidence base is still developing. For the fatigue and mitochondrial burden that accumulates from months of sleep-fragmented nights, mitochondrial peptides like MOTS-c have been researched for cellular energy metabolism. For the broader systemic fatigue that some women in the menopausal transition experience beyond the vasomotor symptoms themselves — brain fog, exhaustion, reduced resilience — Epitalon and similar peptides have been explored in research adjacent to aging and mitochondrial function. These are not treatments for hot flashes. They are conversations about support for the systemic burden of what sustained vasomotor disruption does to sleep quality, energy, and recovery over time.

The honest framing is this: vasomotor symptoms in menopause are in the domain of mainstream gynecology and menopause medicine. Effective treatments exist — both hormonal and, now, specifically non-hormonal. The mechanism has been identified and targeted therapeutically. The gap between the experience and available treatment is not a knowledge gap about what works; it is access, provider training, and the legacy of overcautious prescribing following the WHI misinterpretation. Many women who could benefit from MHT are not offered it because their primary care providers aren't confident prescribing it; many women who could benefit from fezolinetant don't know it exists.

If you are losing sleep to night sweats multiple nights a week, or managing daytime hot flashes that interrupt your function, or cycling through layers and fans and damp sheets in a pattern that is wearing you down — this is not a condition to simply endure. It is one of the better-treated conditions in menopause medicine, once you are in the hands of a clinician who is trained in it. A menopause specialist or a gynecologist with formal training in menopause management can evaluate your hormone picture, your cardiovascular and bone density baseline, your personal history, and your preferences, and build a treatment plan that actually addresses what's happening in the neurons that have been misfiring since estrogen stopped holding them quiet. The biology is understood now. The treatments exist. The question is finding the provider who knows how to apply them.